Vivian (Mingyue) Li, Ph.D., MBA

• Participated in all aspects of investment transactions, including deal sourcing, analysis, due diligence, valuation, negotiation, and portfolio management • Formulated early-stage (Angel/Seed -series A) healthcare investment deals for the investment committee and took a leadership role in analyzing specific investment opportunities and sectors • Sourced & evaluated 100+ startups (therapeutics and diagnostics), led technical/commercial due diligence, and collaborated with KOLs to assess scientific merit, IP, and other strategy

• Created and managed project plans to deliver assays aligned with project milestones. Worked closely with matrix teams to harmonize timelines, budgets, and deliverables • Developed immunological assays (e.g., MLR, T cell proliferation/activation, and monocyte activation assays) to evaluate the immune suppression activity of targets to enable Commit to Target milestone decision • Led target validation by assessing target potentials on genetics, tractability, biology (MOA and expression), in vivo, safety, and competition, in Arthritis, Lupus, Asthma, Gastrointestinal, and other autoimmune diseases • Biology expert on due diligence for Business Development opportunities

• Evaluated and summarized BD deal details in licensing and company-wide acquisitions; Analyzed each transaction’s distinct strategies and objectives; • Established broad connections with big pharma and biotech; Sourced deal opportunities

• In charge of scientific design of pancreatic cancer projects, characterized the heterogeneity in metabolic adaptations to different culture conditions, and assessed the sensitivity of tumor cells to standard-of-care chemotherapy • Led team to execute projects, supported financial department with the instruments’ procurement, and scheduled/managed meetings with clear agenda

• Discovered novel targets (TNFAIP8/TIPE family) in cancer metastasis (Hippo/PI3K pathways) and immune regulation (T-cell biology), earning the Outstanding Presentation Award at Penn Immunology Forum. • Therapeutic development: Systematically studied c-Rel as a myeloid checkpoint for cancer immunotherapy; Designed specific inhibitors for this target as a potential drug candidate; participated in potential licensing negotiations • Translational biomarkers: Supported clinical trials via biomarker discovery/analysis/application in oncology

• Mechanistic studies: Designed and performed in vitro and in vivo candidate characterization (anti-tumor/anti-metastasis) and explored underlying mechanisms of bioactive compounds and Turmeric extract in colorectal cancer, including effective dose-finding, PK profile and PD biomarker (Awarded Global Research Excellence Prize) • Safety/toxicity profiling: Conceived and performed safety assessments (acute toxicity) of small molecules • Collaboration builder: Gathered information on cutting-edge technologies for colorectal cancer treatment, established new collaborations in research institutes and hospitals

• Biotech Due Diligence & Investment Sourcing: Conducted thorough due diligence on healthcare startups, providing in-depth feasibility analyses and risk assessments to inform investment decisions across diverse portfolios, including oncology, HIV, diabetes, and technology platforms etc. • Biotech Due Diligence & Investment Sourcing: Conducted thorough due diligence on healthcare startups, providing in-depth feasibility analyses and risk assessments to inform investment decisions across diverse portfolios, including oncology, HIV, diabetes, and technology platforms etc. • Managed site visits for due diligence; Supported market research for investment decisions and presented to investment boards; Facilitated cross-functional discussions with R&D teams and financial teams

o Conducted target validation for oncology and metabolic diseases; Developed high throughput and high content screening platforms to profile hits and leads for both small molecules and biologics; Experienced in GMP and automation o Led and managed a group of 6 people focusing on high throughput and high content screening using cellular assay systems; Closely collaborated with the chemistry department to help with compound design and SAR (Structure-activity relationship) analysis; Transferred bioassays to CMC; Contributed twice to the “Outstanding Team” award recognition